Physician profile
Mark T Pollock
NPI 1659372415
$2,809.53
in general payments reported to CMS, 2019-2025
28 companies · $517 in 2025
The $517 reported for 2025 was more than what a typical Sleep Medicine (Internal Medicine) provider received nationally (typical 2025 total: $447).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $868 · 2020: $239 · 2021: $126 · 2022: $278 · 2023: $482 · 2024: $299 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,275 · Consulting Fee: $23.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,274.76 |
| Consulting Fee | $23.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $547.13 | 2019-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Inspire Medical Systems, INC. | $488.35 | 2023-2025 | Inspire |
| Astrazeneca Pharmaceuticals Lp | $300.57 | 2019-2024 | Tezspire, Fasenra |
| Jazz Pharmaceuticals INC. | $169.48 | 2021-2022 | |
| Zoll Respicardia, INC. | $168.89 | 2025 | Remede System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.05 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2020 | |
| Eisai INC. | $116.64 | 2019 | |
| Novartis Pharmaceuticals Corporation | $95.01 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $83.39 | 2019-2021 | |
| Genentech USA, INC. | $78.34 | 2019 | |
| Grifols USA, LLC | $71.85 | 2022-2023 | Prolastin-C Liquid |
| Insmed, INC. | $49.50 | 2022-2023 | Arikayce |
| Mallinckrodt Hospital Products INC. | $47.83 | 2023 | Acthar |
| Paratek Pharmaceuticals, INC. | $44.72 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noctrix Health, INC. | $30.62 | 2025 | Nidra |
| Mallinckrodt Enterprises LLC | $29.46 | 2019 | |
| Csl Behring | $27.84 | 2021 | |
| Adma Biomanufacturing LLC | $23.16 | 2024 | |
| Pulmonx Corporation | $20.62 | 2024 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Daiichi Sankyo INC. | $19.88 | 2019 | |
| Genzyme Corporation | $19.75 | 2019 | |
| Mylan Specialty L.P. | $19.72 | 2022 | |
| Philips North America LLC | $18.48 | 2024 | (Ak6) Vest Therapy |
| Harmony Biosciences LLC | $16.53 | 2023 | Wakix |
| Amgen INC. | $15.45 | 2023 | Tezspire |
| Merck Sharp & Dohme LLC | $13.26 | 2019 | |
| Inogen, INC. | $11.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Pollock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.